Determination of idarubicin and idarubicinol in rat plasma using reversed-phase high-performance liquid chromatography and fluorescence detection.
A reversed-phase high-performance liquid chromatographic method is described for the simultaneous determination of idarubicin and idarubicinol in rat plasma. Blood samples were analyzed from 16 rats which had received an intravascular dose of 2.25 mg kg(-1) idarubicin. After deproteinization with acetonitrile, the separation was performed with a LiChrospher 100 RP-18 column (5 microm), using fluorescence detection (excitation: 485 nm/emission: 542 nm). The mean recovery was 95.6% for idarubicin and 90.7% for idarubicinol, respectively. The detection limit was 0.25 ng ml(-1) using an injection volume of 50 microl. Daily relative standard deviation (RSD) was 3.2% (10 ng idarubicin/ml, n=10) and 4.4% (10 ng idarubicinol/ml, n=10).
Kuhlmann
O
O
Department of Pharmacology and Toxicology, Martin-Luther-University, Germany.
Hofmann
S
S
Weiss
M
M
D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000097:blood*; D002851:Chromatography, High Pressure Liquid / Q000379:methods*; D003630:Daunorubicin / Q000031:analogs & derivatives* / Q000097:blood; D015255:Idarubicin / Q000097:blood*; D008297:Male; D051381:Rats; D017208:Rats, Wistar; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity; D013050:Spectrometry, Fluorescence
D000903:Antibiotics, Antineoplastic; C054440:idarubicinol; D015255:Idarubicin; D003630:Daunorubicin